Oral Answers to Questions

Debate between Norman Lamb and Mims Davies

Thursday 7th March 2019 Commons Chamber

[Mims Davies]

As I said, there has been an investigation and lessons will be learned. I am due to meet the Charity Commission fairly shortly. The Government increased the commission’s budget by £5 million in January 2018 so that it could increase its core regulatory functions. I admit that I have had issues in my own constituency relating to concerns about the Charity Commission, so I am happy to take the matter further. I am the charities and lotteries Minister and, as we heard earlier, if we do not have confidence in our charities’ ability to make sure that they look after other people’s money properly, we need to carry on and do more.

[Norman Lamb (North Norfolk) (LD)]

8. What steps his Department is taking to improve mobile phone coverage throughout the UK.

Social Media and Screen Use: Young People’s Health

Debate between Norman Lamb and Mims Davies

Thursday 7th February 2019 Commons Chamber

[The Parliamentary Under-Secretary of State for Digital, Culture, Media and Sport (Mims Davies)]

This is the second time this week that I find myself in the same room as the right hon. Gentleman, agreeing on many issues and focusing on our children’s mental health. That feels very appropriate in Children’s Mental Health Week. As we have heard today, social media is one of many factors that may contribute, in both a positive and negative way, to our children’s mental health. We recognise that social media and technology can bring huge benefits for our young people, but we need to recognise and manage potential harms.

I welcome the Science and Technology Committee’s report and the opportunity to better understand the relationship between young people’s mental health, excessive screen time and the use of social media. We will consider the Committee’s findings ahead of the publication of the online harms White Paper. The report calls for media companies to have a duty of care. We are seriously considering all regulatory options as part of the White Paper. In the meantime, the Government are very clear that we need to hold companies to account. They have a responsibility to their users. We will be setting out plans for both legislative and non-legislative measures in our online harms White Paper.

We continue to work with our colleagues in the Department of Health and Social Care on all possible policy options to take forward on young people’s mental health in relation to all areas of health and social media. All relevant Ministers across Government will see and react to this very good report.

[Norman Lamb]

I thank the Minister very much. Just to be clear, the other occasion when the Minister and I were in a room together was when we talked about the national lottery’s work on children’s mental health. It is making a very significant investment, in six places around the country, in looking at how we can give children the best possible start to life. That is worth applauding.

I welcome the Minister’s response. All I would say is that I encourage her to get on with it. We have been waiting for quite a long time now, and we need the White Paper to be published as soon as possible. Harms continue to happen while we wait for the legislation to be introduced.

Valproate and Foetal Anticonvulsant Syndrome

Debate between Norman Lamb and Mims Davies

Thursday 19th October 2017 Commons Chamber

[Mims Davies]

I thank my hon. Friend for her intervention. Many of us have constituents, friends or family who are affected by epilepsy, which, in itself, is very serious, or by bipolar disorder. Appropriate use remains very important. For the vast majority of patients, treatment can be effective and useful if it is done right—if managed, if educated and if understood. The argument, therefore, should not be about ceasing use, but about telling the truth and looking at appropriate use during pregnancy. Men use the drug too, so we need to take a balanced approach and reflect all situations.

[Norman Lamb]

The hon. Lady is making really good points. I totally agree with her that the drug is appropriate for most people. I just want the guidance to be followed. The guidance is clear that for women of childbearing age it should not be used unless there is no alternative. We just need to stick to that guidance and make sure it is implemented everywhere.

[Mims Davies]

Absolutely. Speaking about this issue in this Chamber will empower our women constituents, before and during pregnancy, so they can be informed and make the right choices. That is the outcome we should all be hoping for.

Similar issues were raised yesterday during a debate in Westminster Hall on mesh implants. New mothers in particular had taken the advice they were given without hesitation. A woman’s first pregnancy can be an unsettling time with all the changes their body goes through. I would imagine that for people suffering from epilepsy or bipolar disorder that time is even more nerve wracking. It is absolutely right that we are measured when we talk about these issues.

It is important that our specialists ensure that women are given the correct and proper guidance. Patients need knowledge and they need it more than anyone. They live with the consequences if things go wrong and they will always look back on their decisions. If they have not been given the right information, how can they truly know they have made the right decision for themselves and their family? Siblings are often impacted as well.

The Government and MPs have a really important role to play in raising awareness of medical issues during pregnancy, including those concerning sodium valproate. I recognise the efforts that have been made, with labelling on packages. I am sure the Minister will agree, however, that more needs to be done. This drug, introduced in 1974, has been crucial, but support for families affected is also crucial. I welcome the fact that young people who have been affected are to be included in the new framework for health and social care for children and young people. It has been a real battle, but clinical commissioning groups and local authorities are getting to grips with it. It is really important that they receive support on a local level. I welcome the Minister’s forthcoming meeting with the all-party group, and I know that Ministers are taking this matter seriously, but I ask the Department for assurances on similar health issues affecting women, such as those relating to Primodos and mesh implants. We have moved to an incredible place on blood contamination—some of my constituents were affected by that—and constituents have written asking me to raise this issue too. We want more action, and there is a common denominator.